Please wait a minute...
文章检索
预防医学  2020, Vol. 32 Issue (11): 1091-1095    DOI: 10.19485/j.cnki.issn2096-5087.2020.11.003
  论著 本期目录 | 过刊浏览 | 高级检索 |
四价流感病毒裂解疫苗安全性和免疫原性评价
刘书珍1, 孟丽2, 席佩佩2, 张勇朝2, 范蓓2, 李长贵1, 夏胜利3, 潘若文2
1.中国食品药品检定研究院,北京 102629;
2.华兰生物疫苗股份有限公司;
3.河南省疾病预防控制中心
Safety and immunogenicity of a split-virion quadrivalent influenza vaccine
LIU Shuzhen*, MENG Li, XI Peipei, ZHANG Yongchao, FAN Bei, LI Changgui, XIA Shengli, PAN Ruowen
*National Institutes for Food and Drug Control, Beijing 102629, China
全文: PDF(874 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价某公司生产的四价流感病毒裂解疫苗(四价流感疫苗)安全性和免疫原性。方法 选择河南省舞阳县和西平县≥3岁的健康人群为研究对象,按照1∶1∶1随机纳入试验组、对照1组和对照2组,分别接种四价流感疫苗、三价流感疫苗(不含Bv型)和三价流感疫苗(不含By型);检测接种前后血凝抑制(HI)抗体滴度,分析接种后疑似预防接种异常反应(AEFI)发生率、HI抗体阳转率、HI抗体保护率和几何平均滴度(GMT)增长倍数,并与欧盟和美国食品药品管理局(FDA)制定的流感疫苗质量标准(HI抗体阳转率>40%、HI抗体保护率>70%和HI抗体GMT增长倍数>2.5)比较。结果 纳入2 924人,其中试验组975人,对照1组974人,对照2组975人。接种后30 min~<8 d,试验组AEFI发生率为11.7%,高于对照1组的7.9%和对照2组的8.8%(P<0.05)。试验组H1N1型、H3N2型、By型和Bv型HI抗体阳转率分别为78.5%、53.3%、78.3%和62.9%,试验组与对照2组By型HI抗体阳转率的率差为42.1%(95%CI:38.0%~46.2%),与对照1组Bv型HI抗体阳转率的率差为33.2%(95%CI:28.9%~37.5%),95%CI的下限均>-0.10。试验组、对照1组和对照2组各型HI抗体GMT增长倍数均≥2.5。试验组H1N1型、H3N2型、By型和Bv型HI抗体保护率分别为87.7%、98.7%、93.6%和77.2%,其中By型HI抗体保护率高于对照2组的71.1%(P<0.05),Bv型HI抗体保护率高于对照1组的51.0%(P<0.05)。结论 接种某公司四价流感疫苗后,H1N1型、H3N2型、By型和Bv型的HI抗体阳转率、HI抗体保护率和GMT增长倍数均达到欧盟和FDA制定的流感疫苗质量标准,该四价流感疫苗的安全性和免疫原性与同公司的三价流感疫苗(包括不含Bv型、不含By型)处于同一水平。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘书珍
孟丽
席佩佩
张勇朝
范蓓
李长贵
夏胜利
潘若文
关键词 四价流感病毒裂解疫苗三价流感病毒裂解疫苗安全性免疫原性    
AbstractObjective To evaluate the safety and immunogenicity of a split-virion quadrivalent influenza vaccine.Methods The healthy people aged three years or over in Wuyang County and Xiping County of Henan Province were divided into the experimental group, control group 1 and control group 2, and were vaccinated with split-virion quadrivalent influenza vaccines, split-virion trivalent influenza vaccines (without B/Victoria) and a split-virion trivalent influenza vaccines (without B/Yamagata) , respectively. The hemagglutination inhibition (HI) antibodies were detected before and after immunization. The incidence rate of adverse events following immunization (AEFI) , HI antibody positive conversion rate, the protection rate of HI antibodies and the growth of geometric mean titer (GMT) were calculated and compared with the standard of Food and Drug Administration (FDA).Results Totally 2 924 people were recruited, with 975 in the experimental group, 974 in the control group 1 and 975 in control group 2. The incidence rate of AEFI in the experimental group was 11.7%, higher than 7.9% in control group 1 and 8.8% in control group 2 (P < 0.05) during 30 minutes and 8 days after inoculation. The positive conversion rates of HI antibodies of H1N1, H3N2, By and Bv in the experimental group were 78.5%, 53.3%, 78.3% and 62.9%, respectively. The rate differences of the positive conversion rates of HI antibodies of By between the experimental group and control group 2, and of Bv between the experimental group and control group 1 were 42.1% (95%CI: 38.0%-46.2%) and 33.2% (95%CI: 28.9%-37.5%) , with both lower limits of 95%CI more than -0.10. The GMT increase of HI antibodies was more than 2.5 times in the three groups. The protective rates of HI antibodies of H1N1, H3N2, By and Bv in the experimental group were 87.7%, 98.7%, 93.6% and 77.2%, respectively. The protective rates of HI antibodies of By in control group 2 and Bv in control group 1 were 71.1% and 51.0%, both lower than those in the experimental group (P < 0.05).Conclusions After the inoculation of the quadrivalent influenza vaccine, the positive conversion rates (>40%) , protection rates (>70%) and GMT increase (>2.5 times) of HI antibodies of H1N1, H3N2, By and Bv all meet the quality standards of FDA. The safety and immunogenicity of the quadrivalent influenza vaccine are not inferior to those of the trivalent influenza vaccine.
Key wordssplit-virion quadrivalent influenza vaccine    split-virion trivalent influenza vaccine    safety    immunogenicity
收稿日期: 2020-06-22      修回日期: 2020-08-28      出版日期: 2020-11-10
中图分类号:  R186  
通信作者: 潘若文,E-mail:prw0023@hualan.com   
作者简介: 刘书珍,大专,副主任医师,主要从事生物制品的质量控制及研究工作;共同第一作者孟丽,硕士,主要从事疫苗生产管理工作
引用本文:   
刘书珍, 孟丽, 席佩佩, 张勇朝, 范蓓, 李长贵, 夏胜利, 潘若文. 四价流感病毒裂解疫苗安全性和免疫原性评价[J]. 预防医学, 2020, 32(11): 1091-1095.
LIU Shuzhen, MENG Li, XI Peipei, ZHANG Yongchao, FAN Bei, LI Changgui, XIA Shengli, PAN Ruowen. Safety and immunogenicity of a split-virion quadrivalent influenza vaccine. Preventive Medicine, 2020, 32(11): 1091-1095.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2020.11.003      或      http://www.zjyfyxzz.com/CN/Y2020/V32/I11/1091
[1] World Health Organization.Vaccines against influenza WHO position paper - November 2012[J]. Wkly Epidemiol Rec,2012,87(47):461-476.
[2] 冯录召,康敏,陈涛,等. 中国流感疫苗预防接种技术指南(2018—2019)[J]. 中华预防医学杂志,2018,52(11):1413-1425.
[3] CRÉPEY P,DE BOER P T,POSTMA M J,et al. Retrospective public health impact of a quadrivalent influenza vaccine in the United States[J]. Influenza Other Respir Viruses,2015(Suppl.1):39-46.
[4] RUDENKO L,KISELEVA I,KRUTIKOVA E,et al. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines:protective vaccine efficacy in the ferret model[J/OL]. PLoS One,2018,13(12)[2020-08-28]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0208028.
[5] XIE H,WAN X F,YE Z,et al. H3N2 mismatch of2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps[J/OL]. Sci Rep,2015[2020-08-28]. https://www.nature.com/articles/srep15279. DOI:10.1038/srep15279.
[6] 吴建华,赵越. 四价流感疫苗预防季节性流感的研究[J]. 中华实验和临床病毒学杂志,2013,27(4):319-321.
[7] 李雪迎. 非劣效性设计样本量估算——计数指标[J]. 中国介入心脏病学杂志,2016,24(6):346.
[8] 中华人民共和国国家食品药品监督管理局. 国家药监局关于发布预防用疫苗临床试验不良事件分级标准指导原则的通告(2019年第102号)[EB/OL]. [2020-08-28]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/200510140 10101369_2.html.
[9] 张群慕,廖晓伟. 流感疫苗的不良反应及其发生机制的研究进展[J]. 华西药学杂志,2016,31(3):321-323.
[10] 王娅宁,张海祥,侯延丽,等. 疫苗严重不良反应及其发生机制研究进展[J]. 中国免疫学杂志,2014,30(2):283-286.
[11] YANG D Y,BRACKEN K.Update on the new 9-valent vaccine for human papillomavirus prevention[J]. Can Fam Physician,2016,62(5):399-402.
[12] 武文娣,李克莉,许涤沙,等. 中国2015—2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J]. 中华预防医学杂志,2019,53(10):987-992.
[13] TINOCO J C,PAVIA-RUZ N,CRUZ-VALDEZ A,et al.Immunogenicity,reactogenicity,and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years:a phase III,randomized trial[J]. Vaccine,2014,32(13):1480-1487.
[14] 姚伟,苏波,沈吉友,等. 四价流感病毒裂解疫苗安全性及免疫原性研究[J]. 微生物学免疫学进展,2018,46(4):7-12.
[15] 吴虓飞,金鑫,胡宇驰,等. 四价流感病毒裂解疫苗的安全性研究[J]. 国际生物制品学杂志,2014,37(5):209-211.
[16] KAI C,XU K,TANG R,et al.Immunogenicity and safety of an inactivated quadrivalent influenza vaccine:a randomized, double-blind,controlled phase III study in healthy population aged ≥3 years[J]. Vaccine,2020,38(37):5940-5946.
[17] 郭雪,马燕丽,康艳先,等. 流感病毒裂解疫苗接种人体后的安全性和免疫原性研究[J]. 中华微生物学和免疫学杂志,2018,38(5):361-365.
[18] 杨北方,邓鹏,郭雪,等. 国产无硫柳汞三价流感病毒裂解疫苗上市后免疫原性和安全性观察[J]. 中国疫苗和免疫,2019,25(2):180-183,214.
[19] 张佩如,祝小平,周良君,等. 国产流行性感冒病毒裂解疫苗安全性及免疫效果观察[J]. 中华预防医学杂志,2009,43(7):615-618.
[20] LUGOVTSEV V Y,VODEIKO G M,STRUPCZEWSKI C M,et al.Generation of the influenza B viruses with improved growth phenotype by substitution of specific amino acids of hemagglutinin[J]. Virology,2007,365(2):315-323.
[1] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[2] 蔡德雷, 徐彩菊, 鹿伟, 夏勇, 张世鑫, 马雪, 宋燕华. 大鼠亚慢性摄入高剂量铁皮石斛的健康效应研究[J]. 预防医学, 2023, 35(5): 452-455,459.
[3] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[4] 华倩慧, 徐校平, 吕华坤, 张杭杰, 蒋健敏. 特定人群接种新冠病毒疫苗的安全性和有效性研究进展[J]. 预防医学, 2022, 34(5): 479-482.
[5] 李萍萍, 罗丽, 吴一峰, 叶莉霞. 老年人接种三价流感病毒裂解疫苗的免疫原性评价[J]. 预防医学, 2022, 34(3): 277-281.
[6] 陈海燕, 王立, 柴鹏飞, 陈建军. 野生梭子蟹和养殖梭子蟹镉含量比较[J]. 预防医学, 2021, 33(2): 192-193.
[7] 严峻, 蔡德雷, 夏勇, 傅剑云, 张世鑫, 孟真, 郑云燕. 醇类免洗手消毒液毒理学安全性研究[J]. 预防医学, 2021, 33(11): 1182-1186.
[8] 傅剑云, 宋燕华, 郑云燕, 朱周靓, 何佳维, 夏勇. 铁皮石斛花对亲代及子代大鼠睾丸组织和精子质量的影响[J]. 预防医学, 2020, 32(5): 442-445.
[9] 吴晓峰, 鲍思雯, 周正豪, 黄思源, 金燕. 杭州市市售菲律宾蛤仔卫生状况调查[J]. 预防医学, 2019, 31(9): 943-945,949.
[10] 夏勇, 傅剑云, 蔡德雷, 张世鑫, 徐彩菊, 陈苘, 严峻. 某栀子复方中药制剂的安全性评价[J]. 预防医学, 2019, 31(8): 786-790,794.
[11] 刘世科, 陈伟, 王帆, 胡莉莉, 章海斌, 胡丹标, 黄美林, 葛怡哲. 婴幼儿接种EV71疫苗的安全性观察[J]. 预防医学, 2019, 31(5): 505-507.
[12] 孟真, 郑云燕, 严峻, 傅剑云, 朱周靓, 张世鑫, 周忭. 某中药育发液外用的毒理学研究[J]. 预防医学, 2019, 31(5): 465-469,473.
[13] 潘雪娇, 符剑, 沈灵智, 吕华坤, 肖艳慧, 陈海平, 石煊雯. EV71疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2019, 31(11): 1097-1099,1104.
[14] 黄巍, 周晓红, 席胜军, 朱建慧, 桂娟娟, 王婷婷. 两种EV71型灭活疫苗安全性比较[J]. 预防医学, 2018, 30(4): 356-358,363.
[15] 曾滢, 陈鲁粤, 杨忠华, 汪婷婷, 梁晓峰, 王富珍, 崔富强, 杜伟民, 蒋征刚, 姚军. 16岁及以上人群接种60 μg重组乙肝疫苗安全性及免疫原性研究[J]. 预防医学, 2017, 29(9): 869-873.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed